Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
News|Articles|February 17, 2016
Capsugel and Pulmatrix Collaborate on Pulmonary Disease Treatments
Author(s)Pharmaceutical Technology Editors
The collaboration will allow the companies to develop and manufacture novel inhaled therapeutics.
Advertisement
Capsugel and Pulmatrix formed a collaboration to develop and manufacture novel inhaled therapeutics for pulmonary diseases, according to a Feb. 16, 2016 press announcement from the companies. The agreement provides Capsugel exclusive rights to manufacture clinical trial and commercial batches of iSPERSE -based inhaled therapeutic candidates being developed by Pulmatrix and its potential development partners.
iSPERSE is a dense and dispersible-engineered particle technology that enables pulmonary delivery of drugs with high delivery efficiency, dose reproducibility, and flow-rate independence. Several products leveraging the iSPERSE platform are in development, two of which are a clinical stage bronchodilator (PUR0200) for chronic obstructive pulmonary disease, and an inhaled anti-fungal (PUR1900) for cystic fibrosis.
“This collaboration provides us with access to Capsugel’s spray dry technology, scale-up capabilities, and state-of-the-art equipment to support our growing pipeline of internal and partnered development programs,” said Robert Clarke, PhD, CEO of Pulmatrix in a press announcement.
Source:
Advertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
3
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
4
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
5